ivWatch Executive Vice President of Sales and Business Development, Scott Hensley, addresses an infusion pump pressure alarm misconception in the area of infiltration detection, and its potential for patient harm in the MedTech Intelligence article, “Product Myths Put Patient Safety at Risk.” He discusses the importance of transparency from the medical device industry to hospitals, so they are best equipped to use technology to impact and provide better clinical outcomes for the patient. Read the full article here.

Brian Clare, M.D. recognized for
business pursuits and philanthropic efforts

HAMPTON, Va., March 4, 2019 – Brian Clare, M.D. chief medical officer and member of
the Board of Directors at ivWatch, a medical device manufacturer and
biosensor technology company focused on improving patient safety and the
effectiveness of intravenous (IV) therapy, gained recognition as an
Inside Business 2019 Health Care Hero
during the publication’s annual breakfast March 4 at Norfolk Waterside
Marriott. Dr. Clare was recognized as the winner in the ‘Innovations in
Health Care’ category for his efforts during his long-standing medical
career as an emergency medicine physician and for his work locally helping
companies gain critical access to resources.

“Dr. Clare is all business when
it comes to medicine,” remarked program judge Kathryn Barrett of Barrett Communications
and former WVEC-TV medical editor.

The Health
Care Heroes awards epitomize the spirit embodied in the word “hero” in the
delivery of health care in the Hampton Roads community; Clare’s reach extends
far beyond. Notable achievements include creating one of the first Scribe
companies in the United States helping physicians with documentation overburden,
and helping secure regulatory clearance for the ivWatch Model 400, a medical device that offers hospitals
and health care facilities a means to protect patients from a common
complication of IV therapy.

“Brian has
been very entrepreneurial in medicine and on the leading edge of developing new
markets to correct health care inefficiencies,” said Gary Warren, president and
CEO of ivWatch. “Brian’s guidance has been instrumental in helping us secure
many of our most important milestones.”

In addition
to his advisory roles at ivWatch and other organizations based in Hampton Roads,
Clare leads the board of Richmond-based non-profit World Pediatric Project as Chairman, providing
life-saving care for critically ill children in the Caribbean and Central
America.

About
ivWatch:ivWatch,
LLC is a medical biosensor technology company focused on
improving patient safety and the effectiveness of intravenous therapy. Our
dedicated and passionate team is pioneering the use of optical sensors to
detect adverse IV events early to minimize the risk of injury caused by
infiltrations and extravasations. By using this technology, clinicians are able
to leverage continuous monitoring to help identify infiltrations as early as
possible. Our innovative monitored IV solutions are backed by decades of
clinical research and device development. To learn more, follow us on
Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch
is pleased to sponsor the work of myIV.com,
an online resource dedicated to empowering visitors with information on all
things IV, simplified.

Pioneeringefforts to address a common IV therapy complication brought into focus at upcoming association programs

HAMPTON, Va., February 6, 2019 – Several nursing associations have incorporated ivWatch representatives and customers in educational programming to present the latest advances in using sensor technology to identify peripheral IV infiltration/extravasation events earlier than ever before to reduce patient injury.

The Infusion Nurses Society (INS) ‘Talking in Vein’ podcast series is part of the association’s learning center and a forum to discuss infusion-related topics with clinical experts, patient advocates and industry leaders. Launching today is a show with guests Mary Alexander MA, RN, CRNI, CAE, FAAN, CEO of Infusion Nurses Society and Gary Warren, president and CEO of ivWatch. The podcast, “Infiltration: Not What We Thought It Was,” reviews misconceptions about IV failure. During the show Warren discusses how technology can impact and provide better clinical outcomes but asserts it should not replace clinical critical thinking.

In her final remarks, Alexander concludes,
“It’s helpful that devices such as ivWatch will warn us of an impending
infiltration, however I can’t stress enough the importance of nursing
assessment and patient feedback. I do believe there is a nice marriage between
practice and technology, and I think it’s important that we’ve got the right
balance with the two.”

The discussion showcases the willingness of professional associations
and medical device manufacturers to work together to review the real-world implications of novel technology. Additional
upcoming events where
experts will share their work combating the potential for injury from
peripheral IV infiltration/extravasation include:

On February 13, Gregory Schears, MD, a pediatric intensivist and anesthesiologist at the Mayo Clinic will facilitate a live webinar session “Short Peripheral Catheter Infiltration: Minimizing Risks to Improve Outcomes,” hosted by the Infusion Nurses Society.

Through educational initiatives like these along with sponsorship of the platform myIV.com, ivWatch showcases continued commitment to improving patient safety and outcomes. To learn more about ivWatch and upcoming event participation, visit www.ivWatch.com/events/.

About ivWatch:ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

HAMPTON, Va., December 11, 2018 – ivWatch, the only provider of continuous patient monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently entered into a distribution agreement with Sedeer Medical Services. Sedeer Medical Services is a major provider and distributor of medical and health care products in Qatar.

Upon completion of regulatory approval requirements, Sedeer Medical will distribute and provide training and support for the ivWatch Model 400 patient monitor to new customers as the exclusive distributor in Qatar.

“With a joint mission of working to set new standards of care in the field of quality health care, we are confident Sedeer Medical will be successful in introducing ivWatch breakthrough technology to hospitals and facilities in search of the best solution for early detection of peripheral IV leakage,” said Scott Hensley, vice president of sales and business development at ivWatch.

About ivWatch:ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. www.ivwatch.com

HAMPTON, Va., December 5, 2018 – ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, recently had two patent applications granted by the Australian and Japanese Patent Offices expanding the company’s intellectual property (IP) portfolio. ivWatch now owns nine patents around the world corresponding to their proprietary breakthrough technologies.

The granting of Australian Patent No. 2013257212 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be independent of the dressings that cover infusion sites during IV therapy or integrated within. This Australian grant comes on the heels of the company announcing an Australia and New Zealand distribution agreement with New Medical, a supplier of medical consumables, devices and patient monitoring accessories.

“Our research and development efforts allow us to continually innovate,” said Gary Warren, president and CEO of ivWatch. “Protecting the resulting breakthroughs of those efforts as we expand into new markets ensures patients have highly effective early detection technology no matter where they are receiving medical treatment.”

This core technology is related to ivWatch’s fourth Japanese patent grant, Registration No. 6396904, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors where patient motion produces unwanted noise. By mitigating the effects of changing tissue blood volume, the system minimizes “false” notifications. Reliable early detection of these events paves the way for a new standard of care to minimize injuries associated with the common complication of IV therapy.

About ivWatch:ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLC. www.ivwatch.com

Peripheral IVs have flown under the radar & their complications have been underreported, undocumented and often ignored. This includes complications like IV infiltration/extravasation - our top priorities.

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.